Arcutis Biotherapeutics, Inc. ARQT

Rank #2458 · Nasdaq · $4.0B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

16.5

P/E

-15.3

P/B

19.14

ROE

-125.1%

Op. Margin

-404.5%

Debt Ratio

91%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -15.3x, P/B 19.14x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -125.1%. Ranks in the top 94% of the universe.

Safety ★★★☆☆

Good

Debt ratio 91%. Ranks in the top 36% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 1517.1% year over year. Ranks in the top 0% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	–	$-0.0B	$-0.0B	$-0.0B	–	-111
2021	–	$-0.0B	$-0.0B	$-0.0B	–	-115
2022	$0.0B	$-0.1B	$-0.1B	$-0.1B	–	-170
2023	$0.0B	$-0.2B	$-0.2B	$0.3B	–	89
2024	$0.0B	$-0.3B	$-0.3B	$0.3B	-8183.0	85
2025	$0.1B	$-0.2B	$-0.3B	$0.2B	-404.5	91